What's Happening?
The FDA has approved Restylane Contour for the treatment of temple hollowing, a common sign of facial aging. This approval allows the Rubinstein Plastic Surgery Center in Montvale, NJ, and Laser & Cosmetic Surgery Specialists in Newburgh, NY, to offer
this treatment as part of their comprehensive injectable services. Restylane Contour, formulated with Galderma's XpresHAn Technology, is designed to integrate with surrounding tissue, providing natural-looking volume restoration while maintaining facial movement. This new indication extends the use of Restylane Contour, which was previously approved for cheek augmentation and midface contour deficiencies, to address volume loss in the temples, a subtle yet impactful area of the face.
Why It's Important?
The approval of Restylane Contour for temple hollowing is significant as it addresses a frequently overlooked aspect of facial aging. Temple volume loss can alter the overall facial structure, contributing to an aged appearance even when other areas of the face remain youthful. By expanding the use of Restylane Contour, patients now have access to a treatment that can restore balance and harmony to the face, enhancing overall aesthetic outcomes. This development is particularly relevant for individuals seeking non-surgical options for facial rejuvenation, offering a solution that aligns with the growing demand for minimally invasive cosmetic procedures.
What's Next?
With the FDA's approval, patients interested in addressing temple hollowing can consult with Dr. Ran Y. Rubinstein at his practices in New Jersey and New York. The expanded indication of Restylane Contour supports a comprehensive approach to facial rejuvenation, allowing for treatment plans that consider the face as a unified structure. This holistic approach may lead to more natural and satisfying results for patients. As the use of Restylane Contour grows, it may set a precedent for further approvals of similar treatments, potentially broadening the scope of non-surgical facial rejuvenation options available to patients.
